







Journal of Research in Pharmacy

ernational open-access journal of pharmacy and pharmaceutical sciences
Formerly published as Marmara Pharmaceutical Journal

Change User MENU Return to Main Page Manuscript Template Logout

Reviewer Comments
 In the part of "5.3. Characterization of gel loading EGCG", "an gel" should be corrected "a gel".

In the concept of characterization of gels, hardness test should be detailed due to elastic nature of gels. How did you achieve correct measurement. Referred article is about suppository which is differ from gel formulation.

This is an original study investigating the intravaginal delivery of reverse micellar epigallocathecin loaded gel. You can find the comments in the attachment.

Editor's Comment File

Comment File Show Comment File

Processing Status: Major Revision

Manuscript	Information
------------	-------------

Manuscript ID:	MPJ-8559
Title in English:	Intravaginal delivery of reverse micellar epigallocathecin loaded in κ -carrageenan and HPMC K100M-based gel
Small Title in English:	No information entered
Authors:	Noorma Rosita ¹ , Dewi Melani Hariyadi ¹ , Cordelia Calista Amelia ² , Alyajilan Madani Mamurrie ² , Andang Miatmoko ¹
Institutions:	¹ Faculty of Pharmacy, Universitas Airlangga, Department of Pharmaceutical Sciences, Surabaya, Indonesia ² Bachelor Program of Pharmacy, Surabaya, Indonesia ³ S Stem Cell Rasearch and Development Center, Universitas Airlangga, Surabaya, Indonesia
Keywords in English:	$\label{prop:prop:prop:prop:prop:general} Epigallocatechin gallate ; cancer ; hydroxypropyl methyl cellulose ; k-carageenan ; reverse micelle ; cervical penetration$
Manuscriet Type:	Decearch article

A gel with mucoadhesive properties and a controlled release profile is considered a suitable dosage form for reverse micellar EGCG delivery. In this study, x-Carrageenan and HPMC K100M were used as the gel components at a weight ratio of 1.1.5 respectively for loading native and reverse micellar EGCG. The characteristics of the gel were determined on the basis of pH, swelling index, disintegration time, hardness, and entrappent efficiency. The in vitro EGCG release rate was further determined for EGCG levels. Moreover, in vivo cervical penetration studies of hiodamine-labelled EGCG gels in mice at two and six hours after intravaginal administration were conducted. The results showed that the pH and hardness characteristics of the gels for each formula did not differ intravaginal administration were conducted. The results showed that they have a hardness characteristics of the gels for each formula did not differ intravaginal administration were conducted. The results showed that they have that material that the EGCG gels in the activity and the cervical penetration of thodamine-labelled reverse micellar EGCG loaded in gels were higher than those of rhodamine-labelled entities EGCG gels. It can be concluded that loading reverse miceller EGCG in the concluded that loading reverse miceller EGCG in the control of the penetration, thereby enabling its potential use in cervical cancer treatment.

File Name	File Size	Date Created	Category	Description
MPJ-8559-4-cover-letter.pdf	33 KB	Jan 14, 2022	Cover letter	None
MPJ-8559-1-manuscript.pdf	591 KB	Jan 14, 2022	Main Document	None
MPJ-8559-6-fig-1.jpg	298 KB	Jan 14, 2022	Figure	None
MPJ-8559-3-fig-2.jpg	197 KB	Jan 14, 2022	Figure	None
MPJ-8559-9-fig-3.jpg	314 KB	Jan 14, 2022	Figure	None
MPJ-8559-9-fig-4.jpg	309 KB	Jan 14, 2022	Figure	None
MPJ-8559-7-ethicla-clearance.pdf	182 KB	Jan 14, 2022	Ethical commission approval	None
MPJ-8559-6-ethicla-clearance.pdf	0 KB	Jan 14, 2022	Supplementary material	None
MPJ-8559-2-jrp-checklist.pdf	436 KB	Jan 14, 2022	Author Checklist Form	None
MPJ-8559-7-jrp-copyright-form-integrated-1pdf	909 KB	Jan 14, 2022	Copyright Transfer Form	None

This is an original study investigating the intravaginal delivery of reverse micellar epigallocathecin loaded gel. The comments are listed below.

Comment 1: The short title must be added.

Comment 2: Abbreviations should be defined at first mention and used consistently thereafter.

(e.g. MMP). In addition, which cells the cell culture lines belong to can be given in parentheses. (e.g. HeLa)

Comment 3: On page 2, under the title "2.1. Physical characteristic of gel loading reverse micellar EGCG"", it was stated that the gel hardness of formulas was approximately 49.75 N, indicating that they were produces in acceptable physical forms. Please add the relevant reference.

Comment 4: On the page 3, the heading "In vivo penetration of gels loading EGCG" should be numbered.

Comment 5: On page 3, under the title "3. Discussion", the space must be added when typing HPMCK100.


Comment 6: On the page 5, under the title "5.4. Evaluation of ECGC released from gels", I think you wrote "270 g" instead of "270 mg". Please, correct it.

Comment 7: The statistical analysis part is missing in the study. For example, it has been mentioned that "there was a significant difference in the rate of release or EGCG flux....." in the results section, but there is no information about the statistical method used. In addition, statistical analysis should be performed for other data (e.g. Swelling index, release, flux, depth of penetration, etc.) The statistical method and program used should be specified in the method section.

Comment 8: It should be added how many replications of the experimental studies were made (n=?). Also, are the data in Table 1 given as Mean ± Standard deviation or Mean ± Standard error? It should be added to the table head. Indication of the polymers used in the preparation of the gels and their ratios in the title of the table/figure unnecessarily lengthens the title [e.g. Table 1, Figure 1 (likewise giving the release conditions), Figure 2]

Comment 9: The error bars (in the form of standard error or standard deviations) should be added to Figure 1 and Figure 4.

Comment 10: The name of the formulations (gel or ovule) should be written uniformly throughout the text and figures. While gel is used throughout the text, ovule is used in the figures.







irespharm.com/s








File I	Name	File Size	Date Created	Category	Description
	cover-letter.pdf	33 KB	Jan 14, 2022	Cover letter	None
	nanuscript.pdf	591 KB	Jan 14, 2022	Main Document	None
	l-6-fig-1.jpg	298 KB	Jan 14, 2022	Figure	None
	1-3-fig-2.jpg	197 KB	Jan 14, 2022	Figure	None
	1-9-fig-3.jpg	314 KB	Jan 14, 2022	Figure	None
	-9-fig-4.jpg	309 KB	Jan 14, 2022	Figure	None
	cla-clearance.pdf	182 KB	Jan 14, 2022	Ethical commission approval	None
	p-checklist.pdf	436 KB	Jan 14, 2022	Author Checklist Form	None
	ht-form-integrated-1pdf	909 KB	Jan 14, 2022	Copyright Transfer Form	None
	t-revised-2-final.rev-1.pdf	607 KB	Mar 28, 2022	Main Document	None
	ver-comment-upload.rev-1.pdf	306 KB	Mar 28, 2022	Response to Reviewers	None
	g-1-rev.rev-1.jpg	314 KB	Mar 28, 2022	Figure	None
	g-2-rev.rev-1.jpg	171 KB	Mar 28, 2022	Figure	None
	g-3-rev.rev-1.jpg	314 KB	Mar 28, 2022	Figure	None
	g-4-rev.rev-1.jpg	318 KB	Mar 28, 2022	Figure	None
Score Sheet 1. Reviewer					
Does the content and value					
of the work justify publication in Marmara Pharmaceutical Journal ?	Yes				
Does the title of the manuscript reflect the contents of the study?	Yes				
Are the keywords sufficient and appropriate ?	Yes				
Is the summary concise and informative?	Yes				
Is the text divided appropriately according to the article type ?	Yes				
Is the language adequate?	Yes				
Are the nomenclature and scientific terminology correct?	Yes				
Are the references complete and recent?	Yes				
Are the figures tables and graphics necessary?	Yes				
Are the figures tables and graphics clear?	Yes				
is the introduction part	sufficiently developed				
Are the experimental procedures sound?	Yes				
Is the results and discussion part	sufficiently developed				
Is conclusion sufficient and correlated with the results?	Yes				
Is the information about the approval of ETHICAL COMMISSION presented ?	Yes				















purc	
Is conclusion sufficient and correlated with the results	
Is the information about th approval of ETHICAL COMMISSION presented ?	Yes
2. Reviewer	
Does the content and value of the work justify publication in Marmara Pharmaceutical Journal ?	e After revision
Does the title of the manuscript reflect the contents of the study?	Yes
Are the keywords sufficient and appropriate?	Yes
Is the summary concise an informative?	nd Yes
Is the text divided appropriately according to the article type ?	Yes
Is the language adequate?	Yes
Are the nomenclature and scientific terminology correct?	Yes
Are the references completed and recent?	te Yes
Are the figures tables and graphics necessary?	Yes
Are the figures tables and graphics clear?	Yes
Is the introduction part	sufficiently developed
Are the experimental procedures sound?	Yes
Is the results and discussion part	sufficiently developed
Is conclusion sufficient and correlated with the results	
Is the information about th approval of ETHICAL COMMISSION presented?	Not applicable









irespharm.com/si









Journal of Research in Pharmacy

mational open-access journal of pharmacy and pharmaceutical sciences Formerly published as Marmara Pharmaceutical Journal

MENU Return to Main Page

I am pleased to inform you that our reviewers have been accepted and recommended your manuscript for publication. Proof of your manuscript will be sent prior to publication. Thank you for choosing to publish in our journal.

Kindest regards, Prof. Dr. Hatice Kubra Elcioglu Editor-in-Chief

Accepted

The state of the s	
Manuscript ID:	MPJ-8559.REV-2
Title in English:	Intravaginal delivery of reverse micellar epigallocathecin loaded in K-carrageenan and HPMC K100M-based gel
Small Title in English:	No information entered
Authora:	Noorma Rosilta ¹ , Dewi Melani Hariyadi ¹ , Cordellia Calista Amelia ² , Alyajilan Madani Mamurrie ² , Andang Miatmoko ¹
Institutions:	Faculty of Pharmacy, Universitas Airlangga, Department of Pharmaceutical Sciences, Surabaya, Indonesia Pacheter Program of Pharmacy, Surabaya, Indonesia "Setem Cell Research and Development Centre, Universitas Airlangga, Surabaya, Indonesia
Keywords in English:	$\label{eq:concern} \textit{Epigallocatechin gallate}; \textit{cancer}; \textit{hydroxypropyl methyl cellulose}; \textit{\kappa-carageenan}; \textit{reverse micelle}; \textit{cervical penetration}$
Manuscript Type:	Research article
Processing Status:	Accepted

A gel with mucoachesive properties and a controlled release profile is considered a suitable dosage form for reverse micellar EGCG delivery. In this study, k-Carrageenan and HPMC K100M were used as the gel components at a weight ratio of 1:1.5 respectively for loading native and reverse micellar EGCG. The characteristics of the gel were determined on the basis of pH, ewelling index, disintegration time, hardness, and entragement efficiency. The in vito EGCG release rate was further determined for EGCG levels. Moreover, in vivo cervical peneration studies of hodium-leabelled EGCG gels in mice at two and six hours after intravaginal administration were conducted. The results showed that the pH and hardness characteristics of the gels for each formula did not differ significantly, while the gel loaded reverse micellar EGCG dot alley the swelling index than that of native EGCG gels. The release and evertical penetration of rhodamine labelled reverse micellar EGCG had alley were higher than those of rhodamine-labelled native EGCG gels. It can be concluded that loading reverse micellar EGCG into gels prepared with x-Carragement and HPMC K100M successfully controlled the release rate and improved cervical penetration, thereby enabling its potential use in cervical cancer treatment.

nuscript Files				
File Name	File Size	Date Created	Category	Descriptio
MPJ-8559-4-cover-letter.pdf	33 KB	Jan 14, 2022	Cover letter	None
MPJ-8559-1-manuscript.pdf	591 KB	Jan 14, 2022	Main Document	None
MPJ-8559-6-fig-1.jpg	298 KB	Jan 14, 2022	Figure	None
MPJ-8559-3-fig-2.jpg	197 KB	Jan 14, 2022	Figure	None
MPJ-8559-9-fig-3.jpg	314 KB	Jan 14, 2022	Figure	None
MPJ-8559-9-fig-4.jpg	309 KB	Jan 14, 2022	Figure	None
MPJ-8559-7-ethicla-clearance pdf	182 KB	Jan 14, 2022	Ethical commission approval	None
MPJ-8559-2-jrp-checklist.pdf	436 KB	Jan 14, 2022	Author Checklist Form	None
MPJ-8559-7-jrp-copyright-form-integrated-1-pdf	909 KB	Jan 14, 2022	Copyright Transfer Form	None
MPJ-9112-5-manuscript-revised-2-final rev-1 pdf	607 KB	Mar 28, 2022	Main Document	None
MPJ-9112-2-answer-to-reviewer-comment-upload rev-1.pdf	306 KB	Mar 28, 2022	Response to Reviewers	None
MPJ-9112-7-fig-1-rev.rev-1.jpg	314 KB	Mar 28, 2022	Figure	None
MPJ-9112-9-fig-2-rev.rev-1.jpg	171 KB	Mar 28, 2022	Figure	None
MPJ-9112-6-fig-3-rev.rev-1.jpg	314 KB	Mar 28, 2022	Figure	None
MPJ-9112-5-fig-4-rev.rev-1.jpg	318 KB	Mar 28, 2022	Figure	None
MPJ-9371-7-manuscript-revised-3-final rev-2.pdf	0 KB	Apr 22, 2022	Main Document	None
MPJ-9371-8-manuscript-revised-3-final rev-2.pdf	485 KB	Apr 22, 2022	Main Document	None
MPJ-9371-3-answer-to-reviewer-comment-upload-2 rev-2 odf	21 KB	Apr 22, 2022	Response to Reviewers	None



